https://www.selleckchem.com/pr....oducts/sodium-ascorb
ubstantial risk of harm. Model updating can mitigate these risks. Care should be taken when using CPMs to guide clinical decision-making. There are significant decreases in model performance when applying cardiovascular disease CPMs to new patient populations, resulting in substantial risk of harm. Model updating can mitigate these risks. Care should be taken when using CPMs to guide clinical decision-making.Aim This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + p
Like
Comment
Share
